3DCRT vs. IMRT in Early Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
It has been not clinically determined whether TomoDirect was dosimetrically better than 3D-CRT for Asian patients with early breast cancer. Therefore, the objective of this study was to compare dosimetric parameters of TomoDirect and 3D-CRT in early breast cancer patients of an Asian cohort.
Epistemonikos ID: 335b60224b957f5b2560b7f348c00fac203f10a9
First added on: May 12, 2024